PROM1 and hepatocellular carcinoma: Both sorted and unsorted cells were treated with sorafenib and subjected to CCK-8 assay in which CD133+ Huh7 showed less cytotoxic/cell death response to sorafenib than CD133−Huh7 and Huh7 cells which verified that CD133+ Huh7 population could contribute to sorafenib resistance in HCC.